Securities Report - 106th Period (2025/04/01 - 2026/03/31)

Kaken Pharmaceutical Co., Ltd. Securities Report - 106th Period (2025/04/01 - 2026/03/31)

Kaken Pharmaceutical Co., Ltd. has published its securities report for the 106th period (April 1, 2025 - March 31, 2026). This report provides a detailed account of the company's performance and financial status during this period.

Regarding the company's performance, sales increased by 10% compared to the previous period, reaching 100 billion yen, and operating profit also increased by 15% compared to the previous period, reaching 15 billion yen. This growth is attributed to the expanded sales of main products and the success of new products.

In terms of financial status, total assets increased by 5% compared to the previous period, reaching 500 billion yen, and the equity ratio also increased by 2 percentage points compared to the previous period, reaching 35%. This strengthening of the financial base is an important step towards the company's future growth strategy.

As for the company's strategic direction, Kaken Pharmaceutical Co., Ltd. plans to further strengthen its investment in research and development and aim to expand into new markets. In particular, the company aims to accelerate its entry into overseas markets and establish itself as a global pharmaceutical company.

This report is an important document for understanding trends in the pharmaceutical industry and the company's strategic direction. It provides valuable information for investors and stakeholders to consider the company's future prospects.